Sanofi ranks slightly below the peer group median, with strong valuation and stability offset by weak profitability. Trend conditions have deteriorated, without yet reaching an extreme downside state. Price action is lagging the structural profile — current market behavior is not yet confirming the structural position.
Peer-relative scores, weakest to strongest
Sanofi is a global pharmaceutical company focused on prescription medicines, vaccines, and consumer healthcare. Its portfolio includes strong positions in immunology and rare diseases, with significant contributions from drugs like Dupixent.
A forward P/E of 9.1x places Sanofi at a discount to the sector median (18.9x), while revenue growth of 6.9% year-on-year indicates that top-line momentum is intact. This valuation gap reflects persistent capital efficiency and margin weaknesses: Sanofi’s quality score remains low (31/100), and the company has ROIC of 6.77% and an operating margin of 14.3%, both below sector leaders. The discount reflects concerns that Sanofi’s capital returns and profitability are not keeping pace with its revenue base.
Sanofi’s quality score has remained at 31/100 over multiple periods, with no upward trend. ROIC at 6.77% is below sector leaders, and the operating margin of 14.3% is modest for a company of this scale and profile. The pipeline—especially in immunology and rare diseases, with Dupixent as a key product—remains robust, but this strength does not offset the core weaknesses in capital returns and margin quality.
Recent external factors add uncertainty. The upcoming CEO transition to Belén Garijo in February 2026 introduces strategic uncertainty, while regulatory pressures in the US and EU continue to affect pricing and approvals for Sanofi and the sector. The high dividend yield (9.36%) does not improve capital efficiency or margin strength.
Compared to peers, Sanofi’s capital efficiency and margin profile are weaker, despite sector-wide regulatory and market headwinds. The valuation gap is partly driven by Sanofi’s inability to raise ROIC and margins to peer levels.
Improvement would require ROIC to reach at least the peer median and operating margins to expand toward sector norms, supported by strategic clarity after the leadership transition. Until then, Sanofi trades at a discount for understandable reasons.
Break down SAN.PA's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.